The University of Southampton
University of Southampton Institutional Repository

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.

Honeychurch, Jamie, Alduaij, Waleed, Azizyan, Mahsa, Cheadle, Eleanor J., Pelicano, Helene, Ivanov, Andrei, Huang, Peng, Cragg, Mark S. and Illidge, Tim M. (2012) Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood, 119, (15), pp. 3523-3533. (doi:10.1182/blood-2011-12-395541). (PMID:22354003).

Record type: Article


Monoclonal antibodies (mAbs) have revolutionized the treatment of B-cell malignancies. Although Fc-dependent mechanisms of mAb-mediated tumor clearance have been extensively studied, the ability of mAbs to directly evoke programmed cell death (PCD) in the target cell and the underlying mechanisms involved remain under-investigated. We recently demonstrated that certain mAbs (type II anti-CD20 and anti-HLA DR mAbs) potently evoked PCD through an actin-dependent, lysosome-mediated process. Here, we reveal that the induction of PCD by these mAbs, including the type II anti-CD20 mAb GA101 (obinutuzumab), directly correlates with their ability to produce reactive oxygen species (ROS) in human B-lymphoma cell lines and primary B-cell chronic lymphocytic leukemia cells. ROS scavengers abrogated mAb-induced PCD indicating that ROS are required for the execution of cell death. ROS were generated downstream of mAb-induced actin cytoskeletal reorganization and lysosome membrane permeabilization. ROS production was independent of mitochondria and unaffected by BCL-2 overexpression. Instead, ROS generation was mediated by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. These findings provide further insights into a previously unrecognized role for NADPH oxidase-derived ROS in mediating nonapoptotic PCD evoked by mAbs in B-cell malignancies. This newly characterized cell death pathway may potentially be exploited to eliminate malignant cells, which are refractory to conventional chemotherapy and immunotherapy.

Full text not available from this repository.

More information

Published date: 12 April 2012
Organisations: Cancer Sciences


Local EPrints ID: 341155
ISSN: 0006-4971
PURE UUID: afa63e6e-c86a-4892-a36c-68adcc39131b
ORCID for Mark S. Cragg: ORCID iD

Catalogue record

Date deposited: 16 Jul 2012 15:25
Last modified: 18 Jul 2017 05:38

Export record



Author: Jamie Honeychurch
Author: Waleed Alduaij
Author: Mahsa Azizyan
Author: Eleanor J. Cheadle
Author: Helene Pelicano
Author: Andrei Ivanov
Author: Peng Huang
Author: Mark S. Cragg ORCID iD
Author: Tim M. Illidge

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.